

In the Sequence Listing:

Please insert the attached paper copy of the Sequence Listing as new pages 1-19 in the above-captioned application. A computer-readable copy (CRF copy) of the Sequence Listing accompanies this response.

AMENDMENTS

In the Claims

Please replace the paragraph beginning at page 2, line 9, ^{in pre Amdt A} with the following rewritten paragraph:

~~33. The antibodies of claim 32 wherein said peptide is human brain natriuretic peptide of the formula:~~

~~R¹-Cys-Phe-Gly-Arg-Lys-Met-Asp-Arg-Ile-Ser-Ser-Ser-Ser-Gly-Leu-Gly-Cys-R² (SEQ ID NO: 5)~~

~~wherein R¹ is selected from the group consisting of:~~

~~(H);~~

~~Gly-;~~

~~Ser-Gly-;~~

~~Gly-Ser-Gly-;~~

~~Gln-Gly-Ser-Gly-;~~

~~Val-Gln-Gly-Ser-Gly-;~~

~~Met-Val-Gln-Gly-Ser-Gly-;~~

~~Lys-Met-Val-Gln-Gly-Ser-Gly-;~~

~~Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-;~~

~~Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-; and~~

~~R³-Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Gly- (SEQ ID Nos: 6-11)~~

~~wherein R³ is the 101 amino acid sequence shown for human BNP in Figure 8 at positions numbered 1-99 immediately upstream of the Ser residue to which R³ is bound, or a C-terminal portion thereof; and-~~

in pre amdt A

Please replace the paragraph beginning at page 3, line 1, with the following rewritten paragraph:

32
-R² is OH, NH₂ or NR₂ wherein each R is independently H or lower alkyl (1-4C); or R² is selected from the group consisting of:
Lys;
Lys-Val;
Lys-Val-Leu;
Lys-Val-Leu-Arg;
Lys-Val-Leu-Arg-Arg; and
Lys-Val-Leu-Arg-Arg-His, or
the C-terminal amides thereof. (SEQ ID NOS: 12-14)

in pre amdt A

Please replace the paragraph beginning at page 3, line 11, with the following rewritten paragraph:

33
-34. The antibodies of claim 33 wherein the peptide is of the formula:
Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-Cys-Phe-Gly-Arg-Lys-Met-Asp-Arg-Ile-Ser-Ser-Ser-Ser-Gly-Leu-Gly-Cys-Lys-Val-Leu-Arg-Arg-His,
or a C-terminal amide thereof. (SEQ ID NO: 49)

in pre amdt A

Please replace the paragraph beginning at page 3, line 22, with the following rewritten paragraph:

34
-37. The antibodies of claim 32 wherein said peptide is canine natriuretic peptide of the formula:
R¹-Cys-Phe-Gly-Arg-Arg-Leu-Asp-Arg-Ile-Gly-Ser-Leu-Ser-Gly-Leu-Gly-Cys-R² (SEQ ID NO: 5)
wherein R¹ is selected from the group consisting of:

(H);
Gly-;
Ser-Gly-;

Lys-Ser-Gly-;

Serial No. 09/902,517
Docket No. 219002025213

34 cont'd

His-Lys-Ser-Gly-;
Met-His-Lys-Ser-Gly-;
Met-Met-His-Lys-Ser-Gly-;
Lys-Met-Met-His-Lys-Ser-Gly-;
Pro-Lys-Met-Met-His-Lys-Ser-Gly-; and

R³-Ser-Pro-Lys-Met-Met-His-Lys-Ser-Gly-; (SEQ ID NOS: 6-11)

wherein R³ is the 100 amino acid sequence of the dog prepro sequence upstream of the Ser residue to which R³ is bound shown in Figure 8 herein or a C-terminal portion thereof;

R² is OH, NH₂, or NR₂ wherein each R is independently H or lower alkyl (1-4C) or R² is

Asn;

Asn-Val;

Asn-Val-Leu;

Asn-Val-Leu-Arg;

Asn-Val-Leu-Arg-Lys; or

Asn-Val-Leu-Arg-Lys-Tyr;

or a C-terminal amide thereof. (SEQ ID NOS: 12-14)

in pre amdt A

Please replace the paragraph beginning at page 4, line 16, with the following rewritten paragraph:

38. The antibodies of claim 37 wherein said canine natriuretic peptide is Ser-Pro-Lys-Met-Met-His-Lys-Ser-Gly-Cys-Phe-Gly-Arg-Arg-Leu-Asp-Arg-Ile-Gly-Ser-Leu-Ser-Gly-Leu-Gly-Cys-Ser-Pro-Lys-Met-Met-His-Lys-Ser-Gly-Asn-Val-Leu-Arg-Lys-Tyr;
or a C-terminal amide thereof. (SEQ ID NO: 50)

In the Specification:

Please replace the paragraph beginning at page 3, line 19, with the following rewritten paragraph:

One of these factors from porcine brain has been isolated and sequenced by Sudoh, P., Nature (1988) 332:78-81. It is a 26-amino acid peptide synthesized in porcine brain and atrial tissue at about 1/100 of the concentration of analyzed atrial natriuretic peptide (ANP) activity. The